Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 15
Submit an article Journal homepage
131
Views
6
CrossRef citations to date
0
Altmetric
Review

Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics

Peng H Tan University of Oxford, The John Radcliffe Hospital, Nuffield Department of Surgery, Headley Way, Oxford, OX3 9DU, UK +44 816 522 1117; [email protected]
&
Amrit S Lota University of Oxford, The John Radcliffe Hospital, Nuffield Department of Surgery, Headley Way, Oxford, OX3 9DU, UK +44 816 522 1117; [email protected]
Pages 2639-2660 | Published online: 19 Sep 2008

Bibliography

  • Lewison EF. The surgical treatment of breast cancer: an historical and collective review. Surgery 1953;34(5):904-53
  • Watson JC, O'Leary JP. History of breast disease: the earliest recordings. Am Surg 1996;62(2):91-2
  • Hadden JW. The immunology and immunotherapy of breast cancer: an update. Int J Immunopharmacol 1999;21(2):79-101
  • Fisher B, Montague E, Redmond C, et al. Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. Cancer 1980;46(1):1-13
  • Fisher B, Redmond C, Fisher ER. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology – an overview of findings. Cancer 1980;46(4 Suppl):1009-25
  • Fisher ER, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4). VI. Discriminants for five-year treatment failure. Cancer 1980;46(4 Suppl):908-18
  • Austyn JM. Death, destruction, danger and dendritic cells. Nat Med 1999;5(11):1232-3
  • Lissoni P, Vigore L, Ferranti R, et al. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J Biol Regul Homeost Agents 1999;13(4):216-9
  • Lespagnard L, Gancberg D, Rouas G, et al. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 1999;84(3):309-14
  • Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297(5588):1867-70
  • Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190(10):1417-26
  • Iwamoto M, Shinohara H, Miyamoto A, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003;104(1):92-7
  • Gabrilovich DI, Corak J, Ciernik IF, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3(3):483-90
  • Satthaporn S, Robins A, Vassanasiri W, et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004;53(6):510-18
  • Della Bella S, Gennaro M, Vaccari M, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003;89(8):1463-72
  • Pinzon-Charry A, Maxwell T, McGuckin MA, et al. Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res 2006;8(1):R5
  • Pinzon-Charry A, Ho CS, Laherty R, et al. A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia 2005;7(12):1112-22
  • Pinzon-Charry A, Maxwell T, Prato S, et al. HLA-DR+ immature cells exhibit reduced antigen-presenting cell function but respond to CD40 stimulation. Neoplasia 2005;7(12):1123-32
  • Fisher ER, Gregorio RM, Redmond C, et al. Pathologic findings from the national surgical adjuvant breast project. (Protocol no. 4). III. The significance of extranodal extension of axillary metastases. Am J Clin Pathol 1976;65(4):439-44
  • Fisher ER, Gregorio R, Redmond C, et al. Pathologic findings from the national surgical adjuvant breast project (protocol no. 4). II. The significance of regional node histology other than sinus histiocytosis in invasive mammary cancer. Am J Clin Pathol 1976;65(1):21-30
  • Menard S, Tomasic G, Casalini P, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997;3(5):817-9
  • Baxevanis CN, Dedoussis GV, Papadopoulos NG, et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994;74(4):1275-82
  • Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54(1):16-20
  • Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51(11):2908-16
  • Sotiropoulou PA, Perez SA, Iliopoulou EG, et al. Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours. Br J Cancer 2003;89(6):1055-61
  • Tuttle TM, Anderson BW, Thompson WE, et al. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 1998;4(8):2015-24
  • Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7(4):452-8
  • Kotera Y, Fontenot JD, Pecher G, et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54(11):2856-60
  • Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18(3):574-83
  • Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr Opin Mol Ther 1999;1(1):98-103
  • Nistico P, Mottolese M, Cascioli S, et al. Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients. Int J Cancer 1999;84(6):598-603
  • Gimmi CD, Morrison BW, Mainprice BA, et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 1996;2(12):1367-70
  • Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54(3):254-64
  • Ercolini AM, Machiels JP, Chen YC, et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003;170(8):4273-80
  • Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7
  • Wilkins DK, Mayer A. Development of antibodies for cancer therapy. Expert Opin Biol Ther 2006;6(8):787-96
  • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
  • Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
  • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
  • Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
  • Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
  • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
  • Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421(6924):756-60
  • Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12
  • Izumi Y, Xu L, Di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416(6878):279-80
  • Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994;91(10):4318-22
  • Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004;5(1):7-10
  • Pinzon-Charry A, Schmidt C, Lopez JA. Dendritic cell immunotherapy for breast cancer. Expert Opin Biol Ther 2006;6(6):591-604
  • Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82
  • Cerundolo V. T cells work together to fight cancer. Curr Biol 1999;9(18):R695-97
  • Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107(4):477-84
  • Clinical Trials; Administration of autologous dendritic cells (DCs) infected with an adenovirus expressing Her-2. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00197522?term=breast+and+dendritic&rank=3 [Last accessed 20 May 2008]
  • Clinical Trials; Biological therapy in treating patients with advanced cancer. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00005956?term=breast+and+dendritic&rank=8 [Last accessed 21 May 2008]
  • Baldus SE, Wienand JR, Werner JP, et al. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int J Oncol 2005;27(5):1289-97
  • Beckhove P, Feuerer M, Dolenc M, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 2004;114(1):67-76
  • Kirkpatrick KL, Clark G, Ghilchick M, et al. hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol 2003;29(4):321-6
  • Poremba C, Heine B, Diallo R, et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 2002;198(2):181-9
  • Amarnath SM, Dyer CE, Ramesh A, et al. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. Int J Oncol 2004;25(1):211-7
  • Nasu S, Yagihashi A, Izawa A, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res 2002;22(3):1839-43
  • Andersen MH, Pedersen LO, Capeller B, et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001;61(16):5964-8
  • Runnebaum IB, Nagarajan M, Bowman M, et al. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 1991;88(23):10657-61
  • Nikitina EY, Clark JI, Van Beynen J, et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001;7(1):127-35
  • Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996;43(3):127-34
  • Jager D, Stockert E, Gure AO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001;61(5):2055-61
  • Sahin U, Tureci O, Chen YT, et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998;78(3):387-9
  • Chen YT, Gure AO, Tsang S, et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998;95(12):6919-23
  • Clinical Trails; Dendritic cell based therapy of metastatic breast cancer. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00197925?term=breast+and+dendritic&rank=1 [Last access 21 May 2008]
  • Svane IM, Pedersen AE, Johansen JS, et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007;56(9):1485-99
  • Dees EC, McKinnon KP, Kuhns JJ, et al. Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother 2004;53(9):777-85
  • Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000;97(6):2715-8
  • Neidhardt-Berard EM, Berard F, et al. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res 2004;6(4):R322-8
  • Kobayashi T, Shinohara H, Toyoda M, et al. Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case. Surg Today 2001;31(6):513-6
  • Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10(14):4699-708
  • Camp BJ, Dyhrman ST, Memoli VA, et al. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol 1996;3(2):176-84
  • Venetsanakos E, Beckman I, Bradley J, Skinner JM. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 1997;75(12):1826-30
  • Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169(5):2756-61
  • Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9(2):606-12
  • Leong PP, Mohammad R, Ibrahim N, et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006;102(2):229-36
  • Mullauer L, Mosberger I, Grusch M, et al. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol 2000;190(1):20-30
  • Sheen-Chen SM, Chen HS, Eng HL, Chen WJ. Circulating soluble Fas in patients with breast cancer. World J Surg 2003;27(1):10-13
  • Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12(5):1599-605
  • Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005;11(7):740-7
  • Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198(4):569-80
  • Yu P, Rowley DA, Fu YX, Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 2006;18(2):226-31
  • Pedersen AE, Thorn M, Gad M, et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol 2005;61(2):147-56
  • Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63(9):2127-33
  • Fay JW, Palucka AK, Paczesny S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 2006;55(10):1209-18
  • Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4(3):328-32
  • O'rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52(6):387-95
  • Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102-8
  • Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201(2):241-8
  • Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254(5038):1643-7
  • Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269(5228):1281-4
  • Wheeler CJ, Das A, Liu G, et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10(16):5316-26
  • Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197(3):387-93
  • Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004;199:251-63
  • Matzinger P. Tolerance, danger, and the extended family. Ann Rev Immunol 1994;12:991-1045
  • Decker D, Tolba R, Springer W, et al. Abdominal surgical interventions: local and systemic consequences for the immune system – a prospective study on elective gastrointestinal surgery. J Surg Res 2005;126(1):12-8
  • Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000;127(2):117-26
  • Klava A, Windsor A, Boylston AW, et al. Monocyte activation after open and laparoscopic surgery. Br J Surg 1997;84(8):1152-6
  • Paterson HM, Murphy TJ, Purcell EJ, et al. Injury primes the innate immune system for enhanced Toll-like receptor reactivity. J Immunol 2003;171(3):1473-83
  • Pillai RG, Beutelspacher SC, Larkin DF, George AJ. Upregulation of chemokine expression in murine cornea due to mechanical trauma or endotoxin. Br J Ophthalmol 2008;92(2):259-64
  • Anderson CC, Carroll JM, Gallucci S, et al. Testing time-, ignorance-, and danger-based models of tolerance. J Immunol 2001;166(6):3663-71
  • Kurts C, Carbone FR, Barnden M, et al. CD4+ T cell help impairs CD8+ T cell deletion induced by cross- presentation of self-antigens and favors autoimmunity. J Exp Med 1997;186(12):2057-62
  • Bingaman AW, Ha J, Waitze SY, et al. Vigorous allograft rejection in the absence of danger. J Immunol 2000;164(6):3065-71
  • Khazaie K, Prifti S, Beckhove P, et al. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 1994;91(16):7430-34
  • Martelli G, Boracchi P, De Palo M, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg 2005;242(1):1-6; discussion 7-9
  • Lee JR, Dalton RR, Messina JL, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003;83(10):1457-66
  • Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9(5):562-7
  • Slavin S, Strober S, Fuks Z, Kaplan HS. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 1977;146(1):34-48
  • Slavin S, Reitz B, Bieber CP, et al. Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts. J Exp Med 1978;147(3):700-7
  • Chao D, Bahl P, Houlbrook S, et al. Human cultured dendritic cells show differential sensitivity to chemotherapy agents as assessed by the MTS assay. Br J Cancer 1999;81(8):1280-4
  • Von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7(5):1181-91
  • Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200(3):297-306
  • Calne RY. 6-Mercaptopurine in renal transplantation. Am J Surg 1979;138(2):338
  • Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65(18):8059-64
  • Keane MM, Rubinstein Y, Cuello M, et al. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 2000;64(2):211-9
  • Keane MM, Ettenberg SA, Nau MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59(3):734-41
  • Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001;7(3):691-703
  • Yu B, Kusmartsev S, Cheng F, et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 2003;9(1):285-94
  • Demaria S, Volm MD, Shapiro RL, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001;7(10):3025-30
  • Kawasaki K, Akashi S, Shimazu R, et al. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000;275(4):2251-4
  • Byrd-Leifer CA, Block EF, et al. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001;31(8):2448-57
  • Coral S, Sigalotti L, Altomonte M, et al. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002;8(8):2690-5
  • Correale P, Aquino A, Giuliani A, et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003;104(4):437-45
  • Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 2004;172(7):4599-608
  • Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62(23):6938-43
  • Emens LA, Machiels JP, Reilly RT, Jaffee EM. Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther 2001;3(1):77-84
  • Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61(9):3689-97
  • Eralp Y, Wang X, Wang JP, et al. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004;6(4):R275-83
  • Clinical Trials; Paclitaxel, cyclophosphamide, and doxorubicin followed by autologous dendritic cells and surgery with or without radiation therapy and/or hormone therapy in treating women with stage II or stage III breast cancer. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00499083?term=breast+and+dendritic&rank=2 [Last access 21 May 2008]
  • Cho BK, Rao VP, Ge Q, et al. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000;192(4):549-56
  • Ge Q, Rao VP, Cho BK, et al. Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/ MHC epitopes and strength of their interaction with T cell receptors. Proc Natl Acad Sci USA 2001;98(4):1728-33
  • Mackall CL, Bare CV, Granger LA, et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996;156(12):4609-16
  • Hu HM, Poehlein CH, Urba WJ, Fox BA. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002;62(14):3914-9
  • Teshima T, Mach N, Hill GR, et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001;61(1):162-71
  • Luznik L, Slansky JE, Jalla S, et al. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2003;101(4):1645-52
  • Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-4
  • Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8(4):299-308
  • Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer 1987;56(5):531-2
  • Bagshawe KD, Springer CJ, Searle F, et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988;58(6):700-3
  • Senter PD, Saulnier MG, Schreiber GJ, et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988;85(13):4842-6
  • Napier MP, Sharma SK, Springer CJ, et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2000;6(3):765-72
  • Springer CJ, Dowell R, Burke PJ, et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 1995;38(26):5051-65
  • Springer CJ, Antoniw P, Bagshawe KD, et al. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem 1990;33(2):677-81
  • Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992;52(8):2127-37
  • Wittliff JL, Fisher B, Durant JR. Establishment of uniformity in steroid receptor analyses used in cooperative clinical trials of breast cancer treatment. Recent Results Cancer Res 1980;71:198-206
  • Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352(9122):93-7
  • Ercoli A, Scambia G, De Vincenzo R, et al. Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism. Cancer Lett 1996;108(1):7-14
  • Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006;24(9):1332-41
  • Belfiglio M, Valentini M, Pellegrini F, et al. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer 2005;104(11):2334-9
  • Carlini P, Bria E, Giannarelli D, et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005;104(7):1335-42
  • Bajetta E, Zilembo N, Barni S, et al. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. Ann Oncol 1997;8(7):649-54
  • Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-47
  • Gasco M, Argusti A, Bonanni B, Decensi A. SERMs in chemoprevention of breast cancer. Eur J Cancer 2005;41(13):1980-9
  • Repetto L, Giannessi PG, Campora E, et al. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res Treat 1996;39(2):235-8
  • Paharkova-Vatchkova V, Maldonado R, Kovats S. Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors. J Immunol 2004;172(3):1426-36
  • Grimaldi CM, Cleary J, Dagtas AS, et al. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002;109(12):1625-33
  • Clinical Trials; Phase II Study with the trifunctional antibody Ertumaxomab to treat metastatic breast cancer progressing after endocrine treatment. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00452140?term=breast+and+dendritic&rank=19 [Last access 21 May 2008]
  • Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004;10(3):294-8
  • Yee C, Savage PA, Lee PP, et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999;162(4):2227-34
  • Kasid A, Morecki S, Aebersold P, et al. Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci USA 1990;87(1):473-7
  • Guy CT, Webster MA, Schaller M, et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992;89(22):10578-82
  • Reilly RT, Gottlieb MB, Ercolini AM, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60(13):3569-76
  • Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201(10):1591-602
  • Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201(5):779-91
  • Muller AJ, Duhadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11(3):312-9
  • Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623-33
  • Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100(14):8372-7
  • Clinical Trials; Vaccine therapy, Trastuzumab, and Vinorelbine in treating women with locally recurrent or metastatic breast cancer. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00088985?term=breast+and+dendritic&rank=5 [Last access 21 May 2008]
  • Withers-Ward ES, Amado RG, Koka PS, et al. Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat Med 1997;3(10):1102-9
  • Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4(10):762-74
  • Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114(2):280-90
  • Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001;2(10):962-70
  • Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99(25):16168-73
  • Gresser I, Bourali C, Levy JP, et al. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci USA 1969;63(1):51-7
  • Hock H, Dorsch M, Kunzendorf U, et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 1993;90(7):2774-8
  • Putzer BM, Hitt M, Muller WJ, et al. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 1997;94(20):10889-94
  • Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996;2(10):1090-5
  • Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4(3):321-7
  • Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA 1996;93(19):10399-404
  • Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92(17):8078-82
  • Shimizu K, Fields RC, Giedlin M, Mule JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999;96(5):2268-73
  • Triozzi PL, Khurram R, Aldrich WA, et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 2000;89(12):2646-54
  • Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007;67(4):1842-52
  • Morse MA, Clay TM, Colling K, et al. HER2 dendritic cell vaccines. Clin Breast Cancer 2003;(3 Suppl 4):S164-72
  • Disis ML, Rinn K, Knutson KL, et al. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 2002;99(8):2845-50
  • Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 2002;51(11-12):669-73
  • Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12(3 Pt 1):869-77
  • Brossart P. Dendritic cells in vaccination therapies of malignant diseases. Transfus Apher Sci 2002;27(2):183-6
  • Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004;10(3):828-39
  • Svane IM, Pedersen AE, Johnsen HE, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004;53(7):633-41
  • Mayordomo JI, Andres R, Isla MD, et al. Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer. Tumori 2007;93(1):26-30
  • Nigam A, Yacavone RF, Zahurak ML, et al. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 1998;12(1):161-70
  • Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001;61(20):7530-5
  • Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105(7):2862-8
  • Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34(2):336-44
  • Schiavoni G, Mattei F, Di Pucchio T, et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000;95(6):2024-30
  • Gorelik L, Rubin M, Prokhorova A, Mokyr MB. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. J Immunol 1995;154(8):3941-51
  • Gorelik L, Mokyr MB. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome. Cancer Immunol Immunother 1995;41(6):363-74
  • Gorelik L, Bar-Dagan Y, Mokyr MB. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J Immunol 1996;156(11):4298-308
  • Mokyr MB, Kalinichenko TV, Gorelik L. Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism. Cell Immunol 1997;178(2):152-61
  • Gorelik L, Prokhorova A, Mokyr MB. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 1994;39(2):117-26
  • Wang J, Kobayashi M, Han M, et al. MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells. Br J Haematol 2002;118(2):638-45
  • Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63(15):4490-6
  • Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002;62(8):2353-8
  • Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170(10):4905-13

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.